Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumour shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show...

Read the whole article on

More from